Get Started
HBV Curricula
Step 1



The Advanced Certificate Program in Chronic Hepatitis B Management V
Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
CME/CE Information

Target Audience

This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, as well as nurse practitioners, nurses, physician assistants, and pharmacists, who specialize in and care for patients with HBV.

Activity Goal

The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.

Learning Objective (s)

  • Assess screening, diagnosis, prevention strategies (eg, vaccination), and optimal treatment interventions of patients with or at risk of chronic HBV infection through an understanding of the epidemiology, risk factors, and disease burden imposed by HBV infection.
  • Analyze cultural differences in patient communication and management of HBV infection (comparing the Asian and Pacific-Islander, Latino, black, and white communities) to bridge these differences and improve patient outcomes.
  • Assess status of molecular tests in determining when to treat, optimal treatment selection and on-treatment response in chronic HBV-infected patients with diverse ethnic backgrounds to improve patient outcomes.
  • Formulate anti-HBV treatment strategies, considering efficacy, therapeutic endpoints, safety, and resistance profiles of current and emerging antiviral agents to improve response rates in culturally diverse patients with chronic HBV infection.
  • Implement optimal treatment selection for special populations with chronic HBV infection to improve outcomes.
  • Integrate personalized anti-HBV prescribing, treatment, and monitoring strategies to prevent, reduce, or manage drug resistance in patients with chronic HBV infection.
  • Analyze barriers to initiating timely anti-HBV treatment interventions and strategies to overcome these barriers in the practice setting.
  • Implement monitoring and follow-up to optimize anti-HBV therapy response for improved patient outcomes (prevent/manage drug resistance, identify/manage therapy-related side effects ensure adherence).


CME Information: Physicians


Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this educational activity for a maximum of 17.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses

Specific credit information can be found on each activity's web page.

CE Information: Pharmacists

Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

CME/CE Instructions


To obtain CME/CE credit:

  1. Read or listen to each activity carefully.
  2. Complete/submit each posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.
Disclosure Information

The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.

Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, and Schering-Plough Corporation; is on the speakers bureau of Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated.

Robert G. Gish, MD has received grant/research support from Bayer/Onyx, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gilead Sciences, Inc, Pharmasset Pharmaceuticals Inc, and ZymoGenetics, Inc; is a consultant for Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, HepaHope, Inc, Human Genome Sciences, Merck & Co, Inc, Metabasis Therapeutics, Inc, OSI/Astellas Pharma US, Inc, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, Three Rivers Pharmaceuticals International, VitalTherapies, and ZymoGenetics, Inc; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International; and is a major stock shareholder of HepaHope, Inc.

W. Ray Kim, MD is a consultant for and is a member of advisory boards for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, and Gilead Sciences, Inc.

Mindie Nguyen, MD, MAS has received grant/research support from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is a member of advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc.

Calvin Pan, MD, FACP, FACG has received grant/research support and is a consultant for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, and Gilead Sciences, Inc; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, F. Hoffmann-La Roche, Ltd, Genentech, Inc, and Gilead Sciences, Inc.

Tram T. Tran, MD has received grant/research support from, is a consultant for, and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc., Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation.

Peer Reviewer has disclosed no relevant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.

Projects In Knowledge's staff members have no relevant relationships to disclose.

These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

1948